Share:
Image Letter

Woronoff Ring in Deficiency of Interleukin-36 Receptor Antagonist (DITRA)

Author Affiliation(s)

Case Presentation

A 54-year-old-man diagnosed with a deficiency of interleukin-36 receptor antagonist (DITRA) under anti-interleukin-1 therapy with anakinra (described elsewhere [ 1 ] ) presented with an erythrodermic pustular psoriasis 5 months after suspension of his biological treatment ( Figure 1A ). Anakinra and topical corticoids were then initiated. Three days later, a halo of nonreddened skin circumscribing an erythematous pustular plaque was observed on his right side ( Figure 1B ). The patient showed a complete clinical response in the following weeks.

Figure 1 .

Woronoff ring in deficiency of interleukin-36 receptor antagonist (DITRA). (A) Widespread erythematous and pustular rash on the trunk. (B) Halo of nonreddened skin circumscribing an erythematous pustular plaque on the right side (3 days after initiating anakinra and topical corticosteroids).

Teaching Point

DITRA is an autoinflammatory disorder caused by mutations in the ILRN36 gene, characterized by abrupt-onset episodes of generalized pustular psoriasis, fever, and systemic involvement. The Woronoff ring is an underrecognized sign of psoriasis, a halo of nonerythematous skin surrounding psoriatic plaques. Its pathogenesis is not fully understood; a relative deficiency of prostaglandins and endoglin has been reported. The Woronoff ring can occur after topical corticoid or tar treatment, fumaric acid esters, phototherapy, biological therapy [ 2 ] , or even in untreated psoriasis.

References

  1. Dynamics of plasma cytokines in a patient with deficiency of interleukin-36 receptor antagonist successfully treated with anakinra Podlipnik S, Morgado-Carrasco D, Fustà-Novell X, et al. Br J Dermatol.2018;178(4):e258-e260.
  2. Woronoff ring associated with adalimumab therapy for psoriasis Park KK, Swan JW, Eilers D, Tung R, Koo J. Cutis.2014;93(2):e1-e2.

Send mail to Author


Send Cancel